European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS

Photoswitchable amphiphilic lipids: a photopharmacology strategy to combat drug-resistant bacterial infections.

Descrizione del progetto

Nuovi antimicrobici attivati dalla luce

La resistenza agli antimicrobici è un problema medico sempre più significativo che comporta l’improvvisa resistenza degli agenti patogeni a trattamenti antibiotici che prima si rivelavano efficaci. Ciò evidenzia la necessità di nuovi farmaci. Al fine di combattere la resistenza agli antimicrobici, il progetto PhotoLiB, finanziato dall’UE, propone di sviluppare farmaci a base lipidica attivabili mediante la luce. L’impiego della luce per modulare le proprietà chimiche dei farmaci è noto come fotofarmacologia e rappresenta un approccio appetibile, in quanto la luce è atossica e può essere applicata con estrema precisione in punti specifici. I farmaci di PhotoLiB saranno in grado di penetrare e alterare le membrane batteriche, fornendo così alternative sicure agli antimicrobici disponibili.

Obiettivo

Antimicrobials have saved millions of lives since they were first discovered. Unfortunately, today the world is facing up a global antibiotic resistance health emergency. In fact, bacterial infections which have been susceptible to standard antibiotic regimes for decades are now becoming resistant to all major antimicrobial treatments, making their efficacy undermined. Within this context, this proposal aims to develop a new and original strategy to combat antimicrobial resistance. Photopharmacology is a novel and emerging medical approach which exploits light to modulate the activity of drugs. The energy of light, which is not toxic to humans and easily delivered with high precision, can be used to change, at will, the conformation and chemical properties of drugs, making them more selective and efficient. This project wants to apply the photopharmacology concept to amphiphilic lipid drugs, namely those molecules bearing a polar head and a lipid tail acting as antimicrobials through disruption of bacterial membranes. Since, unlike other proteins and enzymes, membranes cannot mutate, they are ideal targets to combat antimicrobial resistance. New Photoswitchable Amphiphilic Lipis (PALs), able to intercalate the bacterial membranes, will be developed and synthesised by inserting a photoactivable probe into a amphiphilic lipid. Upon light irradiation, these PALs will change conformation leading, selectively, to membrane damage and consequent cell death. A set of 20 PALs will be synthesised and the compounds will be evaluated against a panel of bacteria, alone or in synergistic combination with other antibiotics. Preliminary in-vivo studies on Galleria models will be carried out as well as NMR-metabolomic studies to elucidate the key interactions of PALs with living systems and the response of bacteria to the action of these new drugs. The data generated through this project will create new means and opportunities in the fight against bacterial resistance.

Coordinatore

UNIVERSITY COLLEGE LONDON
Contribution nette de l'UE
€ 151 686,91
Indirizzo
GOWER STREET
WC1E 6BT London
Regno Unito

Mostra sulla mappa

Regione
London Inner London — West Camden and City of London
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 151 686,91

Partecipanti (1)